Article Details

BioNTech to pay €20M upfront, pick equity stake in Ryvu in license deal for cancer drugs

Retrieved on: 2022-11-30 10:46:22

Tags for this article:

Click the tags to see associated articles and topics

BioNTech to pay €20M upfront, pick equity stake in Ryvu in license deal for cancer drugs. View article details on hiswai:

Excerpt

BioNTech (BNTX) and Ryvu Therapeutics signed a collaboration and license agreement for small molecule programs targeting immune modulation in ...

Article found on: seekingalpha.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up